Mesa Laboratories, Inc. · NASDAQ:MLAB
Mesa Laboratories — Investor Presentation (June 2020)
19 slides from Mesa Laboratories's investor presentation, Jun 1, 2020
Slide 1: Investor Presentation
@MesaLabs Investor Presentation June 1, 2020 Gary Owens, Pr John Sal John Sul
Slide 2: Safe Harbor Statement
Safe Harbor Statement The information provided in this presentation contains forward-looking statements within the meaning ofthe federal securities laws. Any statements contained herein that are not statements of historical fact maybe deemed to be forward-looking statements, including statements rel
Slide 3: Introduction
Introduction MLAB (NASDAQ), public since 1984 Basics ) Headquartered in Denver, Colorado ~475 Employees Diversified quality control instruments, consumables \ What We Do and services for niche applicationsin highly / regulated markets Long term organic growth tailwinds How We Win... Complemented by
Slide 4: Historical Financials — By the Numbers
“ Historical Financials — By the Numbers Revenues FY20 ) $117M te 14% Yor Adjusted Gross Profit % FY20* ) 62% tf 3% YoY AOI Margin % FY20 cxscing wnat items ) 29% 1% YoY CAGR FY10-20 Revenues ) 13% FY17-FY20 Growth Mix ) bait eta with low cyclicality plus Sustainability ) Renewed infrastructure and
Slide 5: FY20 Snapshot
FY20 Snapshot 100% Packaging 4 = when normalied for F121 (ex Packaging, fullyear of PT), Ekenmant, | CAPEK Asia Pacific ROW Gertie 80% OPEX Hardware service 40% Direct 20% Drineton Consumables Division Verticals Revenue Type Geography Channel High quality product mix, attractive end markets, defensi
Slide 6: Year Financial Performance
10 Year Financial Performance mmRevenues —=AO! ==eAOI excluding unusual items ss $120,000 ee ey See $25,000 3 $80,000 $20,000 E 560,000 $15,000 = $40,000 $10,000 $0 $0 ri Fy 3 ria rus rie Fy ris Fo Fr20 Long history of compounding financial returns: 2010-20 CAGR = 13% Revenues; 8% AOI; 12% AOI exclu
Slide 7: Year Share Performance
10 Year Share Performance (r= or0z ‘te Aew) xeput 10.0 0 00 150 100 so (s1eys/$) 9244 a1eys se4020e Soy ator Aewstoe gesst0e Bey c102 ew 102 son s10t Sey sto Soy eto seset0e oy ztoe non Sey ore ew oor 27% CAGR 0% 21% CAGR; S&P 500: compounding share performance: May 2010-20: Defensive stock: S&P 500
Slide 8: The growth we continue to see is driven by our purpose
@MesaLabs The growth we continue to see is driven by our purpose. Our purpose is to Protect the Vulnerable.
Slide 9: Applications
Applications Medical Devices: Healthcare Other | Sterilization & Disinfection Biopharma Development Cont s Cold chain Instruments (Gyros Protcin) Instruments (Oa Monitoring (DidyGuaed) (DryCal/ GI Tora) Mission critical quality applications from Development and Manufacturing through Point of Use
Slide 10: Biopharmaceutical Development
Biopharmaceutical Development Vertical Markets » Biopharmaceuticals immunoassay immunoassay instruments Rapes Growth Drivers ) Y » Biologic drug, cell & gene, vaccine pipelines Immunoassay Peptide Synthesizers Microfluidic Consumables Protein analysis for biopharmaceutical development and peptide sy
Slide 11: Instruments
Instruments Vertical Markets = P| » Healthcare - dialysis = B » Biopharmaceutical » Food & Beverage » Safety & Environmental Dialysis Calibration & Equipment/ Process Standards Validation Data Loggers Growth Drivers » Renal disease » Biopharmaceutical manufacturing » Environmental regulations in hig
Slide 12: Sterilization & Disinfection Control
Sterilization & Disinfection Control Vertical Markets 2a , esac ” onutocaring fea % . oy @) i » Medical Device manufacturing Spore Strip Chemical leaning a: Heckhenesenices Biological Indicators Indicators Verification Growth Drivers = » Biopharmaceutical and u 8 = medical device growth Ef ; » Incre
Slide 13: Cold Chain Monitoring
Cold Chain Monitoring Product Regulatory Performance Compliance ‘Internal Controls Vertical Markets Patient » Biopharmaceutical Safety manufacturing » Healthcare Services Growth Drivers » Recurring revenue from SaaS and new equipment » Increasing adoption in Healthcare Services Continuous monitoring
Slide 14: Growth via Acquisition
Growth via Acquisition HEE instruments EEE Sterilization & disinfection IBP HERE old chain Monitoring Biss Simicon HE Biopharmaceutical Development suretoraae BGI SGM Biotech aoe ‘Apex +14 Int'l Distributors Ainilabo Freshloc PcD Point Six Wireless DataTrace Torgo Amega Infitrak DialyGuard Raven Tem
Slide 15: The Mesa Way!
The Mesa Way! MEASURE WHAT MATTERS WHAT» Customer Driven Strategy » True North KPI's » Strategy Deployment » Enterprise Risk Management HOW _ » Customer-Centric Game Plan » Critical Few » Clear Direction » Stretch Goals EMPOWER TEAMS » Cascade Objectives » Daily Management at Gemba » Initiative Team
Slide 16: Corporate Strategy
Corporate Strategy Portfolio ) Inorganic ) Operating Model ) Niche quality control tools, consumables, and services for highly regulated markets Stable, long term mid single digit organic revenues growth and high margins Niche business with application leadership in high quality markets. Extend reco
Slide 17: Financial Detail
Financial Detail sors nthousansy Fras a7 rvs rv Fv20 Revenues sases0 $03.8 $96,379 103,35 su7ss7 (wren) 19% ux * ™~ as Instruments (evo) % «9 1% cS * Montring (¥0") * om * * (9 Packaging (s¥0") 100% 110% 2% 19% (499, Gross Profit $5143 $55,238 $59618 $00936 364933 ‘Adj Opincome (non-GAAP) saa $247 $
Slide 18: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures (Colters in Thowsands) a Bey || Ge ad ‘Operating Income figszs$igsis_ $288 aye 87438 Amortization of intangible Assets S77 6480 639709010637 ‘toca Compensation Expense 1327 aan sn 432 5525 Imainment loss on Good and Long ved Assets ws a7 26 [Adjusted Operating nom
Slide 19: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures (Dolls in Thousonds) Fras Revenues $04.58 Gross Profit $5443 ros Profit ax Boxeman Relocation Coste Monitoring Inventory Reserves Adjusted Gross Profit? $5143 Adjust Gross Profit ax ros pre ray ris rg | FY20 $9365 $8679 $385 —$1175687 $55258$sa6i9Seosi6 $65,933 sm
Mesa Laboratories — Investor Presentation (June 2020) on 6ix